Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-07-04
2006-07-04
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S034000, C514S183000, C514S185000, C514S284000, C514S492000
Reexamination Certificate
active
07071158
ABSTRACT:
A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.
REFERENCES:
patent: 3479407 (1969-11-01), Laufer
patent: 3576883 (1971-04-01), Neuworth
patent: 4029812 (1977-06-01), Wagner et al.
patent: 4076841 (1978-02-01), Wagner et al.
patent: 4078084 (1978-03-01), Wagner et al.
patent: 4752616 (1988-06-01), Hall et al.
patent: 4954514 (1990-09-01), Kita et al.
patent: 5035878 (1991-07-01), Borch
patent: 5155250 (1992-10-01), Parker
patent: 5206247 (1993-04-01), Regnier et al.
patent: 5215892 (1993-06-01), Kishimoto et al.
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294430 (1994-03-01), Borch
patent: 5348963 (1994-09-01), Gandy et al.
patent: 5360894 (1994-11-01), Kishimoto et al.
patent: 5380747 (1995-01-01), Medford et al.
patent: 5545563 (1996-08-01), Darlington et al.
patent: 5608095 (1997-03-01), Parker et al.
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5750351 (1998-05-01), Medford et al.
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5821260 (1998-10-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 5877203 (1999-03-01), Medford et al.
patent: 6121319 (2000-09-01), Somers
patent: 6147250 (2000-11-01), Somers
patent: 6448019 (2002-09-01), Mendelsohn et al.
patent: 6548699 (2003-04-01), Somers
patent: 6602914 (2003-08-01), Meng
patent: DT 27 16125 (1977-10-01), None
patent: 0292660 (1988-11-01), None
patent: 0418648 (1991-03-01), None
patent: 0348203 (1993-02-01), None
patent: 0621255 (1994-10-01), None
patent: 0405788 (1995-01-01), None
patent: 0763527 (2000-04-01), None
patent: 2168137 (1972-01-01), None
patent: 2130975 (1972-11-01), None
patent: 2133024 (1972-11-01), None
patent: 2134810 (1972-12-01), None
patent: 2140769 (1973-01-01), None
patent: 2140771 (1973-01-01), None
patent: L 136539 (1968-12-01), None
patent: L 199871 (1970-07-01), None
patent: 7-328425 (1995-12-01), None
patent: 8040888 (1996-02-01), None
patent: WO 93/20691 (1993-10-01), None
patent: WO 93/20691 (1993-10-01), None
patent: WO 94/20113 (1994-09-01), None
patent: WO 95/09365 (1995-04-01), None
patent: WO 95/09365 (1995-04-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 95/26719 (1995-10-01), None
patent: WO 95/26719 (1995-10-01), None
patent: WO 95/30415 (1995-11-01), None
patent: WO 96/16989 (1996-06-01), None
patent: WO 97/15546 (1997-05-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
Cheng et al. Cancer Letters (Shannon Ireland) (1990) vol. 51(3) pp. 213-220.
American Heritage Dictionary of the English Language 4thEd. (2000) definitin of “therapeutic index”.
Ripoll et al. J. Urology (1986) vol. 136(2) pp. 529-531.
Yasunaga et al. Archiv Fuer Japnishe Chirurgie (1983) vol. 52(5) pp. 591-601.
Szczepanska et al. Eur. J. Haematology (1988) vol. 40(1) pp. 69-74.
Siveski-Iliskovic et al. Circulation vol. 91, Issue 1 (Jan. 1995) pp. 10-15.
Weijl et al. Cancer Treatment Reviews (Jul. 1997) vol. 23(4) pp. 209-240.
Cloos et al. Carcinogenesis (1996) vol. 17(2) pp. 327-331.
Chinery et al. Nature Medicine vol. 3, No. 11 (Nov. 1997) pp. 1233-1241.
Biosis AN: 1990:428349 Abstract to Archives of Toxicology (1990) vol. 64, No. 5 pp. 393-400.
Embase AN 9227964 Abstract to Anticancer Research (1992) vol. 12 (3) pp. 599-606.
Coffey, et al.,Cancer Res. 47, 4590 (1987).
Crook, et al.Oncogene6, 873 (1991).
Scheffner, et al.Proc. Natl. Acad. Sci. U.S.A. 88, 5523 (1991).
Ripoll, et al., Vitimin E Enhances the Chemotherapeutic Effects of Adriamycin,Biological Abstracts, 82, 82084938.
Yaunaga et al., Vitimin E and Cancer Therapy-Experimental Study in Mice, Database National Cancer Institute, 1982.
Szczepanska et al., Inhibition of Leukocyte Migration by Cancer Chemotherapeutic Agents and its Prevention by Free Radical Scavengers and Thiols, Biological Abstracts vol. 85, 85106445.
Prasad et al., Vitamin E Increases the Growth Inhibitoryuy and Differenciating Effects of Tumor Therapeutic Agents on Neuro Blastoma and Glioma Cells in Culture, Biological Abstracts, vol. 70, 70052454.
Drago, et al., Chemptherapy and Vitamin E in Treatment of NB Rat Prostrate Tumors, Biological Abstracts vol. 88, 88006807.
Cloos Jacqueline Jan, Influence of the antioxidant N-acetylcysteine annd its metabolites on Damage induced by Bleomycin in PM2 Bacteriophage,Biological Abstracts, vol. 96, 98730849.
Riordan et al., Case study: High Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney,J. Orthomolecular Med., 5:1, 1990, 5-7.
Campbell et al., Retticulum Cell Sarcoma: Two Complete “Spontaneous” Regressions, in Response to High-Dose Ascorbic Acid Therapy,Oncology, 48:6 (1991), 495-497.
Bongers, Antioxidant-Related Parameters in Patients Treated for Cancer Chemoprevention with N-acetylcysteine,Biological Abstracts, vol. 95, 98363146.
Offerman, etal. AntooxidantSensitive Regulation of Inflammatory—Response Genes in Kaposi's Sarcoma Cells,J. of AIDS and Hum. Retro., (1996) 13:1-11.
Tyagi S C, Reduction-Oxidation state Regulation of Extracellular Matrix Metalloproteinases and Tissue Inhibitors in Cardiac Normal and Transformed Fibroblast Cells,Biological Abstracts, vol. 96, 98730849.
Roesl, Differential Regulation of the JE Gene Encoding the Monocyte Chemoattractant Protein (MCP-1) in Cervical Carcinoma Cells and Derived Hybrids,Biological Abstracts, vol. 94, 97193049.
Kowens-Leutz, et al., Novel Mechanism of C/EPBbeta (NF-M) Transciptional Control: Activation Through Derepression,Genes and Development, 8:1994, 2781-2791.
Favre et al., The catalytic Subunit of protein Phophatase 2A is Carboxyl-methylated in vivo.J. of Biol. Chem., 269:23, (1994), 16311-16317.
Trautwien et al., Protein Kinease A and C Site-Specific Phosphorylations of LAP (nf-IL6) Modulate its Binding Affinity to DNA Recognition Elements,J. of Clin. Investig., 93:6, (1994) 2554-2561.
WPI Derwent Publications Ltd., 97-373441 1995.
WPI Derwent Publications Ltd., 96-157002 1996.
Chinery, R. et al.Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein betaJournal of Biological Chemistry 272: 30356-30361 (1997).
Chinery , R. et al.Antioxidant-induced Nuclear Translocation of CCAAT/Enhancer-binding Protein betaJournal of Biological Chemistry 272: 30356-30361 (1997).
Berkowitz et al. Tet. Lett. vol. 35, pp. 6445-6448 (Jul. 1994).
Mahoney et al., J. Biol. Chem. vol. 267, No. 27 pp. 19396-19403 (Jul. 1994).
Abstract to Hedricks-Taylor et al. Genomics, vol. 14(1) pp. 12-17 (Jan. 1992).
Advanced Cancer Meta-Analysis Project (P. Piedbois, et al.), “Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate”,J. Clin. Oncol.,10(6):896-903 (Jun. 1992).
Akira, S., et al., “A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family”,EMBO J.,9(6):1897-1906 (1990).
Akira, S., et al., “IL-6 and NF-IL6 in acute phase response to viral infection”,Immunol. Rev.,127:25-50 (1992).
Anderson, T.J., et al., “The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion”,N. Eng. J. Med
Beauchamp R. Daniel
Chinery Rebecca
Coffey Robert J.
Medford Russell M.
Wadzinski Brian E.
Atherogenics, Inc.
Celsa Bennett
King & Spalding LLP
Knowles, Esq. Sherry M.
LandOfFree
Antioxidant enhancement of therapy for hyperproliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antioxidant enhancement of therapy for hyperproliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antioxidant enhancement of therapy for hyperproliferative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587982